webinar register page

Use of Extended Clearance Concept and PBPK Modeling in New Drug Discovery and Development: Predicting Target Tissue Exposure From In Vitro to In Vivo
Dr. Sugiyama will describe “Extended clearance concept” and show the participants how to establish a physiologically based pharmacokinetic (PBPK) model that includes the transporter-mediated membrane transport and enzyme-mediated metabolism processes. In addition, he will explain to the participants how changes in transporter (influx, efflux) function and metabolizing enzyme function affects the pharmacokinetics of drugs in the blood and the liver and, ultimately, the pharmacological and/or toxicological effects.
Key objectives/takeaways from participating.
The participants will be able to:
1. Apply the extended clearance concept in order to establish a physiologically based pharmacokinetic (PBPK) model that includes transporter-mediated membrane transport and enzyme-mediated metabolism processes.
2. Understand the effect of changes in transporter (influx, efflux) function and metabolizing enzyme function on the pharmacokinetics of drugs in the blood and the liver and, ultimately, the pharmacological and/or toxicological effects.

Mar 31, 2021 05:00 PM in Eastern Time (US and Canada)

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Lisa Infelise.